|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rustgi AK and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pevny LH and Lovell-Badge R: Sox genes
find their feet. Curr Opin Genet Dev. 7:338–344. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Masui S, Nakatake Y, Toyooka Y, Shimosato
D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, et
al: Pluripotency governed by Sox2 via regulation of Oct3/4
expression in mouse embryonic stem cells. Nat Cell Biol. 9:625–635.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Que J, Okubo T, Goldenring JR, Nam KT,
Kurotani R, Morrisey EE, Taranova O, Pevny LH and Hogan BL:
Multiple dose-dependent roles for Sox2 in the patterning and
differentiation of anterior foregut endoderm. Development.
134:2521–2531. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gen Y, Yasui K, Zen Y, Zen K, Dohi O, Endo
M, Tsuji K, Wakabayashi N, Itoh Y, Naito Y, et al: SOX2 identified
as a target gene for the amplification at 3q26 that is frequently
detected in esophageal squamous cell carcinoma. Cancer Genet
Cytogenet. 202:82–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bass AJ, Watanabe H, Mermel CH, Yu S,
Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et
al: SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hussenet T, Dali S, Exinger J, Monga B,
Jost B, Dembelé D, Martinet N, Thibault C, Huelsken J, Brambilla E,
et al: SOX2 is an oncogene activated by recurrent 3q26.3
amplifications in human lung squamous cell carcinomas. PLoS One.
5:e89602010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maier S, Wilbertz T, Braun M, Scheble V,
Reischl M, Mikut R, Menon R, Nikolov P, Petersen K, Beschorner C,
et al: SOX2 amplification is a common event in squamous cell
carcinomas of different organ sites. Hum Pathol. 42:1078–1088.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gen Y, Yasui K, Nishikawa T and Yoshikawa
T: SOX2 promotes tumor growth of esophageal squamous cell carcinoma
through the AKT/mammalian target of rapamycin complex 1 signaling
pathway. Cancer Sci. 104:810–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang G, Murashige DS, Humphrey SJ and
James DE: A Positive Feedback Loop between Akt and mTORC2 via SIN1
Phosphorylation. Cell Rep. 12:937–943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zen K, Yasui K, Nakajima T, Zen Y, Zen K,
Gen Y, Mitsuyoshi H, Minami M, Mitsufuji S, Tanaka S, et al: ERK5
is a target for gene amplification at 17p11 and promotes cell
growth in hepatocellular carcinoma by regulating mitotic entry.
Genes Chromosomes Cancer. 48:109–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chresta CM, Davies BR, Hickson I, Harding
T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini
P, et al: AZD8055 is a potent, selective, and orally bioavailable
ATP-competitive mammalian target of rapamycin kinase inhibitor with
in vitro and in vivo antitumor activity. Cancer Res. 70:288–298.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeong HC, Park SJ, Choi JJ, Go YH, Hong
SK, Kwon OS, Shin JG, Kim RK, Lee MO, Lee SJ, et al: PRMT8 Controls
the Pluripotency and Mesodermal Fate of Human Embryonic Stem Cells
By Enhancing the PI3K/AKT/SOX2 Axis. Stem Cells. 35:2037–2049.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh S, Trevino J, Bora-Singhal N,
Coppola D, Haura E, Altiok S and Chellappan SP: EGFR/Src/Akt
signaling modulates Sox2 expression and self-renewal of stem-like
side-population cells in non-small cell lung cancer. Mol Cancer.
11:732012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schaefer T, Wang H, Mir P, Konantz M,
Pereboom TC, Paczulla AM, Merz B, Fehm T, Perner S, Rothfuss OC, et
al: Molecular and functional interactions between AKT and SOX2 in
breast carcinoma. Oncotarget. 6:43540–43556. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maurer U, Preiss F, Brauns-Schubert P,
Schlicher L and Charvet C: GSK-3 - at the crossroads of cell death
and survival. J Cell Sci. 127:1369–1378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Walz A, Ugolkov A, Chandra S, Kozikowski
A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD and Mazar AP:
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a
Target for the Treatment of Cancer. Clin Cancer Res. 23:1891–1897.
2017. View Article : Google Scholar : PubMed/NCBI
|
